Federal Register / Vol. 63, No. 96 /Tuesday, May 19, 1998 / Notices 27589

(September 23, 1975), all applicants for

registration to import a basic class of

any controlled substance in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: May 5, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13331 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances

Notice of Registration

By Notice dated February 13, 1998,

and published in the Federal Register

on March 5, 1998 (62 FR 10944),

Mallinckrodt Chemical Inc.,

Mallinckrodt & Second Streets, St.

Louis, Missouri 63147, made

application by renewal to the Drug

Enforcement Administration to be

registered as an importer of the basic

classes of controlled substances listed

below:

Drug Schedule

Coca Leaves (9040) ................... II

Opium, raw (9600) ...................... II

Opium poppy (9650) ................... II

Poppy Straw Concentrate (9670) II

The firm plans to import the listed

controlled substances to manufacture

bulk finished products.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

Section 823(a) and determined that the

registration of Mallinckrodt Chemical

Inc. to import listed controlled

substances is consistent with the public

interest and with United States

obligations under international treaties,

conventions, or protocols in effect on

May 1, 1971, at this time. Therefore,

pursuant to Section 1008(a) of the

Controlled Substances Import and

Export Act and in accordance with Title

21, Code of Federal Regulations, Section

1301.34, the above firm is granted

registration as an importer of the basic

classes of controlled substances listed

above.

Dated: May 6, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13319 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on January 15,

1998, Novartis Pharmaceuticals Corp.,

59 Route 10, East Hanover, New Jersey

07936, made application by renewal to

the Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of the Schedule II

controlled substance methylphenidate

(1724).

The firm plans to manufacture the

finished product for distribution to its

customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 20,

1998.

Dated: May 5, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13330 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated January 8, 1998, and

published in the Federal Register on

February 4, 1998, (63 FR 5818),

Pharmacia & Upjohn Company, 7000

Portage Road, 2000–41–109, Kalamazoo,

Michigan 49001, made application by

renewal to the Drug Enforcement

Administration (DEA) to be registered as

a bulk manufacturer of 2,5-

dimethoxyamphetamine (7396), a basic

class of controlled substance listed in

Schedule I.

The firm plans to manufacture the

listed controlled substance for

distribution as bulk product to a

customer.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Pharmacia & Upjohn

Company to manufacture 2,5-

dimethoxyamphetamine is consistent

with the public interest at this time.

Therefore, pursuant to 21 U.S.C. 823

and 28 C.F.R. §§ 0.100 and 0.104, the

Deputy Assistant Administrator, Office

of Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic class of

controlled substance listed above is

granted.

Dated: May 6, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13321 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on May 31,

1998, Research Triangle Institute,

Kenneth H. Davis, Jr., Hermann

Building, East Institute Drive, P.O. Box

12194, Research Triangle Park, North

Carolina 27709, made application by

renewal to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

Marijuana (7360) ........................... I

Cocaine (9041) ............................. II

The institute will manufacture

marijuana cigarettes for the National

Institute on Drug Abuse (NIDA) and the

cocaine will be used for reference

standards, human and animal research,

as dictated by NIDA.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to